Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-511-9 | CAS number: 7601-89-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
sodium perchlorate was administered orally and dermally to rats according to OECD Guidelines 423 and 402 respectively.
The LD0 of sodium perchlorate was found to be higher than 2000 mg/kg when administered via the oral or dermal route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 - 24 April 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: 8 weeks
- Weight at study initiation: Males 367 ± 12g; Females 237 ± 7g
- Housing:
Acclimation period: 1 - 7 of same sex in polycarbonate cages with stainless steel lid (48x27x20cm).
Treatment period: individually housed in polycarbonate cages with stainless steel lid (35.5x23.5x19.3cm). Each cage contained autoclaved sawdust (SICSA, Alfortville, France).
- Diet: SSNIFF R/M-H pelleted maintenance diet (ad libitum); SSNIFF Spezialdiaten GmbH, Soest, Germany).
- Water: drinking water filtered by a FG Millipore memmbrane (0.22µm) ad libitum.
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 30-70%
- Air changes (per hr): 12 cycles/hr of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12h/12/h (7:00-19:00)
IN-LIFE DATES: From: 10 April 2008 To: 24 April 2008 - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: Males approx. 5x7cm; Females approx. 5x6cm
- % coverage: approx. 10%
- Type of wrap if used: adhesive hypoallergenic aerated semi-occlusive dressing and a restraining bandage.
REMOVAL OF TEST SUBSTANCE
- Removed using a dry cotton pad
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): as a single dose at 2000mg/kg adjusted according to the bodyweight determined on the day of
treatment
- Concentration (if solution): Applied as its original formbut purified water was used in order to moisten the test item and ensure a good contact with the skin
- Constant volume or concentration used: yes
- For solids, paste formed: no
VEHICLE
Not applicable - Duration of exposure:
- 24 hours
- Doses:
- A single dose (2000 mg/kg bw)
- No. of animals per sex per dose:
- 5 animals/sexe/dose
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Observed for clinical signs frequently soon after dosing and at least once per day thereafter up until day 15.
Bodyweights recorded just before dose administration on day 1 and then on days 8 and 15
- Necropsy of survivors performed: yes - Statistics:
- no
- Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- There were no deaths during the study
- Clinical signs:
- other: No systemic clinical signs were observed during the study. Crusts were noted in 1/5 males (No. 5) from day 10 until day day 15 (end of the observation period)
- Gross pathology:
- Macroscopic examination of the main organs of the animals revealed no apparent abnormalities
- Other findings:
- None
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Regulation (EC) No 1972/2008 on CLP
- Conclusions:
- Under the experimental conditions of this study, the dermal LD50 of the test item was higher than 2000mg/kg in rats
- Executive summary:
The acute dermal toxicity of the test item ANHYDROUS SODIUM PERCHLORATE (batch No. lot moyen du 10/01/08 test) was evaluated in rats according to OECD (No. 402, 24th February 1987) and EC (92/69/EEC, B.3, 31st July 1992) guidelines. The study was conducted in compliance with the principles of Good Laboratory Practice Regulations. Under the experimental conditions of this study, the dermal LD0 of the test item ANHYDROUS SODIUM PERCHLORATE (batch No. lot moyen du 10/01/08 test) was higher than 2000 mg/kg in rats.
Reference
No deaths and no systemic clinical signs were observed during the study (Table 1). Crusts were noted in 1/5 males from day 10 until day 15, (Table 2). When compared to CIT historical control animals, a slightly lower body weight gain was noted in 1/5 females between day 1 and day 8; it returned to normal thereafter. The body weight gain of the other animals was not affected by treatment with the test item (Tables 3 & 4). No apparent abnormalities were observed at necropsy in any animal.
Table 1: Individual clinical signs and mortality
Dose-level (mg/kg) |
Time |
Animals |
Mortality |
Clinical signs |
|
2000 |
Males |
Females |
|||
30 mins |
01-02-03-04-05 |
06-07-08-09-10 |
No |
None |
|
2 hours |
|||||
Day 2 – Day 15 |
Table 2: Cutaneous reactions
Dose-level (mg/kg) |
Time |
Animals |
Cutaneous reactions |
|
2000 |
Males |
Females |
||
Day 2 to Day 9 |
01-02-03-04-05 |
06-07-08-09-10 |
None |
|
|
||||
Day 2 – Day 15 |
05 |
- |
Crusts |
|
01-02-03-04 |
06-07-08-09-10 |
None |
Table 3: Individual and mean body weight and weekly body weight change (g)
Dose level (mg/kg) |
Sex |
Animals |
Days |
||||
1 |
(1) |
8 |
(1) |
15 |
|||
2000 |
Male |
01 |
371 |
37 |
408 |
55 |
463 |
02 |
380 |
43 |
423 |
49 |
472 |
||
03 |
373 |
45 |
418 |
51 |
469 |
||
04 |
353 |
36 |
389 |
49 |
438 |
||
05 |
356 |
37 |
393 |
50 |
443 |
||
|
|||||||
Mean |
367 |
40 |
406 |
51 |
457 |
||
SD |
12 |
4 |
15 |
2 |
16 |
||
|
|||||||
2000 |
Female |
06 |
240 |
35 |
275 |
15 |
290 |
07 |
233 |
12 |
245 |
26 |
271 |
||
08 |
235 |
36 |
271 |
22 |
293 |
||
09 |
247 |
16 |
263 |
15 |
278 |
||
10 |
229 |
38 |
267 |
32 |
299 |
||
|
|
|
|
|
|
||
Mean |
237 |
27 |
264 |
22 |
286 |
||
SD |
7 |
12 |
12 |
7 |
11 |
SD: standard deviation
Table 4: Body weight - CIT historical data of control animals dosed (purified water) by dermal route
Volume (mL/kg) |
Sex |
|
Days |
||||
1 |
(1) |
8 |
(1) |
15 |
|||
5 |
Male |
Mean |
328 |
44 |
372 |
46 |
419 |
SD |
39 |
13 |
35 |
8 |
37 |
||
n |
29 |
29 |
29 |
29 |
29 |
||
|
|||||||
5 |
Female |
Mean |
214 |
25 |
239 |
18 |
257 |
SD |
11 |
11 |
16 |
9 |
20 |
||
n |
30 |
30 |
30 |
30 |
30 |
(1): bodyweight gain
SD: standard deviation
n: number of animals
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
Oral acute :
The acute oral toxicity of the test item sodium perchlorate was evaluated in rats according to OECD (No. 423, 17th December 2001) and EC (2004/73/EC, B.1 tris, 29th April 2004) guidelines. The study was conducted in compliance with the principles of Good Laboratory Practice Regulations. Under the experimental conditions of this study, the oral LD0 of the test item sodium perchlorate was higher than 2000 mg/kg in rats.
Dermal acute :
The acute dermal toxicity of the test item sodium perchlorate was evaluated in rats according to OECD (No. 402, 24th February 1987) and EC (92/69/EEC, B.3, 31st July 1992) guidelines. The study was conducted in compliance with the principles of Good Laboratory Practice Regulations. Under the experimental conditions of this study, the dermal LD0 of the test item sodium perchlorate was higher than 2000 mg/kg in rats.
Justification for classification or non-classification
Oral acute :
According to EU regulation (EC) No 1272/2008 (CLP) and EU Directive 67/584/EEC, anhydrous sodium perchlorate is not classified for acute oral (LD0>2000 mg/kg bw). But according to 19th ATP, anhydrous perchlorate is classified "Harmful is swallowed - R22"; this classification is probably based on human data. Therefore, we keep the classification of sodium perchlorate as "harmful is swallowed" ( R22 according to EU Directive 67/548/EEC, and in Acute toxicity Category 4 of CLP).
Dermal acute :
According to EU regulation (EC) No 1272/2008 (CLP) andEU Directive 67/584/EEC, anhydrous sodium perchlorate is not classified for acute dermal (LD0>2000 mg/kg bw).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.